Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro (Q46409873)
Jump to navigation
Jump to search
scientific article published in January 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro |
scientific article published in January 2005 |
Statements
1 reference
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro (English)
1 reference
1 reference
Keith Dredge
1 reference
Rebecca Horsfall
1 reference
Ling-Hua Zhang
1 reference
Ling Lu
1 reference
Yang Tang
1 reference
Michael A Shirley
1 reference
George Muller
1 reference
Peter Schafer
1 reference
David Stirling
1 reference
Angus G Dalgleish
1 reference
J Blake Bartlett
1 reference
1 January 2005
1 reference
1 reference
69
1 reference
1-2
1 reference
56-63
1 reference
Identifiers
1 reference
1 reference